Ocrelizumab

Therapeutic Group

Immunosuppressants

Indication Dosage

Primary Progressive Multiple Sclerosis, Relapsing Forms Of Multiple Sclerosis: 

By IV Infusion: 

  • Adult: Initially 300 Mg, Then 300 Mg After 2 Weeks; Maintenance 600 Mg Every 6 Months; A Minimum Interval Of 5 Months Should Be Maintained Between Each Maintenance Dose

Content

  • Inj: Ocrelizumab 30mg Per 1 ml; 300mg /10ml Concentrate For Solution For Infusion Vials

Pregnancy

Contraindicated, Use Contraceptives During Treatment And For 12 Months After The Last Dose

Stability

  • Immunosuppressant
  • Anti-lymphocyte Monoclonal Antibodies

Contra Indications

  • Patients With Active Hepatitis B Virus Infection And In Patients With A History Of Life-threatening Infusion Reaction To Ocrelizumab, Active Infection, Active Malignancies, Severely Immunocompromised Patients

Precautions

  • Patients With Active Hepatitis B Virus Infection And In Patients With A History Of Life-threatening Infusion Reaction To Ocrelizumab, Active Infection, Active Malignancies, Severely Immunocompromised Patients

Lactation

  • Contraindicated Discontinue Breast-feeding

Side Effects

  • Anaphylactic Reaction
  • Alopecia
  • Anaemia
  • Arthralgia
  • Asthenia
  • Constipation
  • Diarrhea
  • Cough
  • Cytokine Release Syndrome
  • Depression
  • Dyspnea
  • Fever
  • Flushing
  • Headache
  • Hypertension
  • Hypotension
  • Infusion Related Reaction
  • Leucopenia
  • Nausea
  • Neutropenia
  • Pruritus
  • Sweat Changes
  • Tachycardia
  • Thrombocytopenia
  • Tumour Lysis Syndrome
  • Vomiting
  • Rare: Progressive Multifocal Leukoencephalopathy
  • Hepatitis B Reactivation

Available Brands